back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2019-01-28 Tx date 2019-01-23 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
-150,000 vol |
0 | |
| Filed 2018-12-18 Tx date 2018-11-22 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+150,000 vol |
150,000 | |
| Filed 2018-12-18 Tx date 2018-10-01 |
$ATT
Abattis Bioceuticals Corp. |
Wilson, Cedric Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-11-26 Tx date 2018-11-22 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$13,500
+150,000 vol $0.09 each |
150,000 | |
| Filed 2018-11-26 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-10-23 Tx date 2018-09-28 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$13,500
+100,000 vol $0.135 each |
100,000 | |
| Filed 2018-10-23 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-10-23 Tx date 2018-05-07 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-10-23 Tx date 2018-06-21 |
$ATT
Abattis Bioceuticals Corp. |
McParland, Kent
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,500
+100,000 vol $0.185 each |
100,000 | |
| Filed 2018-09-19 Tx date 2018-09-17 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
$30,000
+200,000 vol $0.15 each |
135,000 | |
| Filed 2018-09-19 Tx date 2018-09-17 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-30,000
-200,000 vol $0.15 each |
-65,000 | |
| Filed 2018-08-10 Tx date 2018-06-18 |
$ATT
Abattis Bioceuticals Corp. |
Abenante, Robert
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 1053345 B.C. Ltd. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$684,336
+4,677,625 vol $0.1463 each |
12,668,322 | |
| Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-08-08 Tx date 2018-04-26 |
$ATT
Abattis Bioceuticals Corp. |
Richter, Wolfgang
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-08-03 Tx date 2018-08-01 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-35,400
-236,000 vol $0.15 each |
1,307,250 | |
| Filed 2018-06-27 Tx date 2018-06-26 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$146,200
+1,000,000 vol $0.1462 each |
10,293,311 | |
| Filed 2018-06-27 Tx date 2018-06-26 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$545,376
+4,277,465 vol $0.1275 each |
14,570,776 | |
| Filed 2018-06-21 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
47 - Acquisition or disposition by gift
|
-1,500,000 vol |
||
| Filed 2018-06-21 Tx date 2018-06-19 |
$ATT
Abattis Bioceuticals Corp. |
David, Rene
5 - Senior Officer of Issuer
Holder: Crimson Opportunities Ltd. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-170,000
-1,000,000 vol $0.17 each |
9,293,311 |